Bigelow Investment Advisors LLC Sells 805 Shares of Pfizer Inc. (NYSE:PFE)

Bigelow Investment Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 4.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 16,112 shares of the biopharmaceutical company’s stock after selling 805 shares during the quarter. Bigelow Investment Advisors LLC’s holdings in Pfizer were worth $408,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Johnson Investment Counsel Inc. lifted its position in Pfizer by 30.0% during the first quarter. Johnson Investment Counsel Inc. now owns 143,433 shares of the biopharmaceutical company’s stock valued at $3,635,000 after purchasing an additional 33,068 shares during the last quarter. Steel Grove Capital Advisors LLC raised its position in shares of Pfizer by 438.1% during the 1st quarter. Steel Grove Capital Advisors LLC now owns 68,822 shares of the biopharmaceutical company’s stock valued at $1,744,000 after buying an additional 56,033 shares in the last quarter. Community Bank N.A. lifted its holdings in shares of Pfizer by 15.1% in the 1st quarter. Community Bank N.A. now owns 89,748 shares of the biopharmaceutical company’s stock valued at $2,274,000 after acquiring an additional 11,796 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of Pfizer by 2.3% in the 1st quarter. State of Alaska Department of Revenue now owns 796,553 shares of the biopharmaceutical company’s stock valued at $20,184,000 after acquiring an additional 17,820 shares during the last quarter. Finally, CWA Asset Management Group LLC grew its position in Pfizer by 4.0% in the first quarter. CWA Asset Management Group LLC now owns 32,184 shares of the biopharmaceutical company’s stock worth $816,000 after acquiring an additional 1,225 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $23.88 on Thursday. The company has a market capitalization of $135.74 billion, a P/E ratio of 17.30, a P/E/G ratio of 0.87 and a beta of 0.57. The company’s 50-day simple moving average is $23.17 and its two-hundred day simple moving average is $24.92. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 earnings per share. Pfizer’s revenue was down 7.8% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.20%. The ex-dividend date was Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PFE shares. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.